Insider Trading Alert - WTFC, FNGN, MXIM, JNPR And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 29, 2014, 48 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,167.07 to $320,146,398.72.

Highlighted Stocks Traded by Insiders:

Wintrust Financial (WTFC) - FREE Research Report

Dykstra David A who is Senior Evp And Coo at Wintrust Financial sold 4,226 shares at $46.02 on Jan. 29, 2014. Following this transaction, the Senior Evp And Coo owned 169,538 shares meaning that the stake was reduced by 2.43% with the 4,226-share transaction.

Stoehr David L who is Chief Financial Officer at Wintrust Financial sold 497 shares at $45.68 on Jan. 29, 2014. Following this transaction, the Chief Financial Officer owned 13,497 shares meaning that the stake was reduced by 3.55% with the 497-share transaction.

Murphy Richard B who is Executive Vice President at Wintrust Financial sold 2,485 shares at $45.45 on Jan. 29, 2014. Following this transaction, the Executive Vice President owned 32,106 shares meaning that the stake was reduced by 7.18% with the 2,485-share transaction.

The shares most recently traded at $44.76, down $0.69, or 1.54% since the insider transaction. Historical insider transactions for Wintrust Financial go as follows:

  • 4-Week # shares sold: 3,998
  • 12-Week # shares sold: 3,998
  • 24-Week # shares sold: 3,998

The average volume for Wintrust Financial has been 350,000 shares per day over the past 30 days. Wintrust Financial has a market cap of $1.8 billion and is part of the financial sector and banking industry. Shares are down 3.23% year-to-date as of the close of trading on Wednesday.

Wintrust Financial Corporation, through its subsidiaries, provides banking and other financial products and services to customers in the Chicago metropolitan area and in southeastern Wisconsin. The company operates in three segments: Community Banking, Specialty Finance, and Wealth Management. The stock currently has a dividend yield of 0.88%. The company has a P/E ratio of 16.5. Currently there are 2 analysts that rate Wintrust Financial a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WTFC - FREE

TheStreet Quant Ratings rates Wintrust Financial as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, expanding profit margins, solid stock price performance, compelling growth in net income and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Wintrust Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Financial Engines (FNGN) - FREE Research Report

Maggioncalda Jeffrey Nacey who is Ceo at Financial Engines sold 15,000 shares at $60.08 on Jan. 29, 2014. Following this transaction, the Ceo owned 10,000 shares meaning that the stake was reduced by 60% with the 15,000-share transaction.

The shares most recently traded at $60.87, up $0.79, or 1.3% since the insider transaction. Historical insider transactions for Financial Engines go as follows:

  • 4-Week # shares sold: 7,329
  • 12-Week # shares sold: 24,337
  • 24-Week # shares sold: 74,291

The average volume for Financial Engines has been 352,600 shares per day over the past 30 days. Financial Engines has a market cap of $3.1 billion and is part of the financial sector and financial services industry. Shares are down 12.28% year-to-date as of the close of trading on Wednesday.

Financial Engines, Inc., together with its subsidiaries, provides independent, technology-enabled portfolio management services, investment advice, and retirement income services to participants in employer-sponsored defined contribution plans. The stock currently has a dividend yield of 0.33%. The company has a P/E ratio of 115.0. Currently there are 3 analysts that rate Financial Engines a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FNGN - FREE

TheStreet Quant Ratings rates Financial Engines as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Financial Engines Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Maxim Integrated Products (MXIM) - FREE Research Report

Doluca Tunc who is President, Ceo & Director at Maxim Integrated Products sold 6,000 shares at $30.00 on Jan. 29, 2014. Following this transaction, the President, Ceo & Director owned 1.2 million shares meaning that the stake was reduced by 0.51% with the 6,000-share transaction.

The shares most recently traded at $29.86, down $0.14, or 0.47% since the insider transaction. Historical insider transactions for Maxim Integrated Products go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 32,646

The average volume for Maxim Integrated Products has been 3.3 million shares per day over the past 30 days. Maxim Integrated Products has a market cap of $8.5 billion and is part of the technology sector and electronics industry. Shares are up 7.24% year-to-date as of the close of trading on Wednesday.

Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs. The stock currently has a dividend yield of 3.48%. The company has a P/E ratio of 20.8. Currently there are 6 analysts that rate Maxim Integrated Products a buy, no analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MXIM - FREE

TheStreet Quant Ratings rates Maxim Integrated Products as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Maxim Integrated Products Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Juniper Networks (JNPR) - FREE Research Report

Denholm Robyn M who is Division EVP CFO & Ops at Juniper Networks sold 40,000 shares at $27.21 on Jan. 29, 2014. Following this transaction, the Division EVP CFO & Ops owned 24,309 shares meaning that the stake was reduced by 62.2% with the 40,000-share transaction.

The shares most recently traded at $27.50, up $0.29, or 1.05% since the insider transaction. Historical insider transactions for Juniper Networks go as follows:

  • 4-Week # shares sold: 39,000
  • 12-Week # shares sold: 39,000
  • 24-Week # shares sold: 85,000

The average volume for Juniper Networks has been 9.4 million shares per day over the past 30 days. Juniper Networks has a market cap of $13.9 billion and is part of the technology sector and computer hardware industry. Shares are up 22.86% year-to-date as of the close of trading on Wednesday.

Juniper Networks, Inc. designs, develops, and sells products and services that provide network infrastructure for networking requirements of service providers, enterprises, governments, and research and public sector organizations worldwide. The company has a P/E ratio of 21.5. Currently there are 11 analysts that rate Juniper Networks a buy, no analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JNPR - FREE

TheStreet Quant Ratings rates Juniper Networks as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Juniper Networks Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 7,500 shares at $8.16 on Jan. 29, 2014. Following this transaction, the CEO & Chairman owned 138.5 million shares meaning that the stake was reduced by 0.01% with the 7,500-share transaction.

The shares most recently traded at $8.06, down $0.10, or 1.24% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.5 million shares per day over the past 30 days. Opko Health has a market cap of $3.3 billion and is part of the health care sector and health services industry. Shares are down 5.57% year-to-date as of the close of trading on Wednesday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Jim Cramer: Intuit Had a Fantastic Quarter

Jim Cramer: Intuit Had a Fantastic Quarter